Method of manufacturing an implantable device
View Patent ↗Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof.
1. A method of manufacturing an implantable device, wherein the implantable device can deliver a therapeutic polypeptide agent to a subject, and the release of the therapeutic polypeptide agent from the implantable device can be modulated by varying the components or the amounts of the components of the implantable device, the method comprising: a) mixing one or more polymerizable monomeric substances; b) adding one or more substances selected from the group consisting of: an excipient, a wetting agent, a non-ionic surfactant, an organic solvent, an alcohol, a reducing agent, an oxidizing agent and an aqueous solvent; and c) subjecting the mixture to conditions that cause the one or more polymerizable monomeric substances to polymerize in the presence of the one or more components, thereby forming the implantable device, wherein the mixture comprises a mixture selected from the group consisting of: a) about 78.72% HEMA (hydroxyethyl methacrylate), about 0.40% EGDMA (ethyleneglycol dimethacrylate), about 0.79% Vitamin E TDGS, about 0.24% BME (benzoin methyl ether), about 0.08% P-16 (Parkadox® 16), about 9.89% water and about 9.89% isopropyl alcohol; b) about 78.72% HEMA, about 0.40% EGDMA, about 0.79% Vitamin E TDGS, about 0.24% BME, about 0.08% P-16 and about 19.78% water; c) about 68.97% HEMA, about 0.35% EGDMA, about 0.69% Vitamin E TDGS, about 0.21% BME, about 0.07% P-16, about 14.85% water and about 14.85% isopropyl alcohol; and d) about 68.97% HEMA, about 0.35% EGDMA, about 0.69% Vitamin E TDGS, about 0.21% BME, about 0.0796 P-16 and about 29.71%.
2. The method of claim 1 , wherein the rate of release of the therapeutic polypeptide can be modulated.
3. The method of claim 1 , wherein the mixture is placed into a mold prior to being subjected to a polymerization step.
4. The method of claim 3 , wherein the polymerization step is initiated by ultraviolet irradiation.
5. The method of claim 1 , further comprising charging the implantable device with a desired amount of a therapeutic polypeptide agent.
6. The method of claim 5 , wherein the therapeutic polypeptide agent comprises a GLP-1 analog.
7. The method of claim 6 , wherein the GLP-1 analog comprises exenatide.
8. The method of claim 1 , wherein the therapeutic polypeptide agent is combined with a wetting agent to form a solid formulation prior to being charged into the implantable device.
9. The method of claim 8 , wherein the solid formulation comprises about 98% exenatide and about 2% stearic acid.